Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2010
  • Online publication date: August 2011

Chapter 14 - Management of ovarian and endometrial cancer in older adults

from Part 2 - Management of solid tumors in older adults
Edwards, BK, Howe, HL, Ries, . Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94:2766–2792.
Yancik, R, Ries, . Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–136.
Thigpen, T, Brady, MF, Omura, GA. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71:606–614.
Hightower, RD, Nguyen, HN, Averette, HE. National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer. 1994;73:377–383.
Pignata, S, Vermorken, JB. Ovarian cancer in the elderly. Crit Rev Oncol Hematol. 2004;49: 77–86.
Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
Ries, , Melbert, D, Krapcho, M. SEER Cancer Statistics Review, 1975–2005. Bethesda, MD: National Cancer Institute; 2008.
Watson, P, Butzow, R, Lynch, HT. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001;82:223–228.
Chen, S, Iversen, ES, Friebel, T. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24:863–871.
Haber, D.Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med. 2002;346: 1660–1662.
Kauff, ND, Domchek, SM, Friebel, TM. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26: 1331–1337.
Chi, DS, Sabbatini, P. Advanced ovarian cancer. Curr Treat Options Oncol. 2000;1:139–146.
Mirhashemi, R, Nieves-Neira, W, Averette, HE. Gynecologic malignancies in older women. Oncology. 2001;15:580–586; discussion 592–594, 597–598.
Lambrou, NC, Bristow, RE. Ovarian cancer in elderly women. Oncology. 2003;17:1075–1081; discussion 1081, 1085–1086, 1091.
Ryerson, AB, Eheman, C, Burton, J. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol. 2007;109:1053–1061.
Winter III, WE, Maxwell, GL, Tian, C. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–3627.
Chan, JK, Loizzi, V, Lin, YG. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?Obstet Gynecol. 2003;102:156–161.
Chan, JK, Urban, R, Cheung, MK. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer. 2006;95: 1314–1320.
Markman, M, Lewis, Jr JL, Saigo, P. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol. 1993;49:236–239.
Petignat, P, Fioretta, G, Verkooijen, HM. Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol. 2004;13:181–186.
Du, XL, Sun, CC, Milam, MR. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer. 2008; 18(4):660–669.
Pectasides, D, Fountzilas, G, Aravantinos, G. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer. 2007;17: 1003–1010.
Bristow, RE, Tomacruz, RS, Armstrong, DK. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259.
Wimberger, P, Lehmann, N, Kimmig, R. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol. 2006;100:300–307.
Uyar, D, Frasure, HE, Markman, M. Treatment patterns by decade of life in elderly women (> or = 70 years of age) with ovarian cancer. Gynecol Oncol. 2005;98:403–408.
Wright, JD, Herzog, TJ, Powell, MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol. 2004;190:1398–1400.
Sharma, S, Driscoll, D, Odunsi, K. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193: 2077–2082.
Eisenhauer, EL, Tew, WP, Levine, DA. Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol. 2007;106:381–387.
Bruchim, I, Altaras, M, Fishman, A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol. 2002;86:274–278.
Nordin, AJ, Chinn, DJ, Moloney, I. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol. 2001;81:447–455.
Cloven, NG, Manetta, A, Berman, ML. Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol. 1999;73: 137–139.
Susini, T, Scambia, G, Margariti, PA. Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol. 1999;75:437–443.
Diaz-Montes, TP, Zahurak, ML, Giuntoli, II RL. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol. 2005;99:352–357.
McGuire, WP, Hoskins, WJ, Brady, MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
Ozols, RF, Bundy, BN, Greer, BE. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21: 3194–3200.
Maas, HA, Kruitwagen, RF, Lemmens, VE. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol. 2005;97:104–109.
Hershman, D, Jacobson, JS, McBride, R. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol. 2004;94:540–549.
Sundararajan, V, Hershman, D, Grann, VR. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol. 2002;20:173–178.
Pignata, S, Monfardini, S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer. 2000;36:817–820.
Pignata, S, Breda, E, Scambia, G. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008:66(3):229–236.
Tredan, O, Geay, JF, Touzet, S. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d';Investigateurs Nationaux pour l';Etude des Cancers Ovariens. Ann Oncol. 2007;18: 256–262.
Fader, AN, Gruenigen, VV, Gibbons, H. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol. 2008.
Group, ICON: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360: 505–515.
Villella, JA, Chaudhry, T, Pearl, ML. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol. 2002;86:316–322.
Ceccaroni, M, D';Agostino, G, Ferrandina, G. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol Oncol. 2002;85:445–450.
Alberts, DS, Liu, PY, Hannigan, EV. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335: 1950–1955.
Markman, M, Bundy, BN, Alberts, DS. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19: 1001–1007.
Armstrong, DK, Bundy, B, Wenzel, L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.
Wenzel, LB, Huang, HQ, Armstrong, DK. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:437–443.
Brenner, BM, Meyer, TW, Hostetter, TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–659.
Launay-Vacher, V, Chatelut, E, Lichtman, SM. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol. 2007;18:1314–1321.
Launay-Vacher, V, Oudard, S, Janus, N. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110:1376–1384.
Lichtman, SM, Wildiers, H, Launay-Vacher, V. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.
Lichtman, SM, Hollis, D, Miller, AA. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006;24:1846–1851.
Lichtman, SM, Wildiers, H, Chatelut, E. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J Clin Oncol. 2007;25: 1832–1843.
Parmar, MK, Ledermann, JA, Colombo, N. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106.
Pfisterer, J, Plante, M, Vergote, I. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707.
Bukowski, RM, Ozols, RF, Markman, M. The management of recurrent ovarian cancer. Semin Oncol. 2007;34:S1–S15.
Gridelli, C, Langer, C, Maione, P. Lung cancer in the elderly. J Clin Oncol. 2007;25: 1898–1907.
Wildiers, H, Kunkler, I, Biganzoli, L. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8:1101–1115.
Gronlund, B, Hogdall, C, Hansen, HH. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer. 2002;94:1961–1967.
Gordon, AN, Tonda, M, Sun, S. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1–8.
Morris, RT.Weekly topotecan in the management of ovarian cancer. Gynecol Oncol. 2003;90: S34–S38.
Kabbinavar, FF, Hurwitz, HI, Yi, J. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009;27:199–205.
Burger, RA.Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol. 2007;25:2902–2908.
Lewin, SN, Buttin, BM, Powell, MA. Resource utilization for ovarian cancer patients at the end of life: how much is too much?Gynecol Oncol. 2005;99:261–266.
Hurria, A, Lichtman, SM, Gardes, J. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc. 2007;55:1604–1608.
Freyer, G, Geay, JF, Touzet, S. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795–1800.
Cella, DF, Tulsky, DS, Gray, G. The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579.
Sweeney, C, Schmitz, KH, Lazovich, D. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst. 2006;98:521–529.
Gruenigen, VE, Gil, K, Huang, H. Quality of life in ovarian cancer patients during chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:S28–S29.
Gruenigen, VE, Frasure, HE, Grandon, M. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103:120–126.
Schink, JC, Weller, E, Harris, LS. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group phase II study (E2E93). J Cancer. 2001;7:155–164.
Bezjak, A, Tu, P, Bacon, M. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004;22:4595–4603.
Wan, GJ, Counte, MA, Cella, DF. An analysis of the impact of demographic, clinical and social factors on health related quality of life. Value Health. 1999;2:308–318.
Movsas, B, Scott, C, Watkins-Bruner, D. Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys. 2006;65: 830–835.
Gil, KM, Gibbons, HE, Hopkins, MP. Baseline characteristics influencing quality of life in gynecologic cancer. Health Qual Life Outcomes. 2007;5:25–32.
Earle, CC, Landrum, MB, Souza, JM. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?J Clin Oncol. 2008;26:3860–3866.
Gruenigen, VE, Daly, B, Gibbons, HE. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer. 2008;112(10):2221–2227.
Bruchim, I, Biron-Shental, T, Altaras, MM. Combination of endometrial thickness and time since menopause in predicting endometrial cancer in women with postmenopausal bleeding. J Clin Ultrasound. 2004;32(5):219–224.
Doorn, HC, Opmeer, BC, Jitze Duk, M. The relation between age, time since menopause, and endometrial cancer in women with postmenopausal bleeding. Int J Gynecol Cancer. 2007;17(5):1118–1123.
Somoye, G, Olaitan, A, Mocroft, A. Age related trends in the incidence of endometrial cancer in South East England 1962–1997. J Obstet Gynaecol. 2005;25(1):35–38.
Olson, JE, Sellers, TA, Anderson, KE. Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case-control family study of older women. Cancer. 1999;85(11):2444–2449.
Farley, JH, Nycum, LR, Birrer, MJ. Age-specific survival of women with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2000;79(1):86–89.
Ueda, SM, Kapp, DS, Cheung, MK. Trends in the demographics and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol. 2008;198(218): E1–E6.
Chan, JK, Tian, C, Monk, BJ. Gynecologic Oncology Group. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008;112(10):2202–2210.
Calle, EE, Rodriguez, C, Walker-Thurmond, K. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
Ahmed, A, Zamba, G, DeGeest, K. The impact of surgery on survival of elderly women with endometrial cancer in the SEER program from 1992–2002. Gynecol Oncol. 2008;111(1):35–40.
Gruenigen, VE, Tian, C, Frasure, H. Treatment toxicity, disease recurrence and survival as related to obesity in women with early endometrial carcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107:2786–2791.
Trimble, EL, Kosary, C, Park, RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol. 1998;71(3):340–343.
Chan, JK, Lin, YG, Monk, BJ. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol. 2001;97(5 Pt 1):707–711.
Susini, T, Massi, G, Amunni, G. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Gynecol Oncol. 2005;96(2):362–367.
Nag, S, Erickson, B, Parikh, S. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 2000;48(3):779–790.
Fader, AN, Michener, CM, Giannios, N. Total laparoscopic hysterectomy versus laparoscopic-assisted vaginal hysterectomy in endometrial cancer: surgical and survival outcomes. J Min Inv Gynecol. 2009;16(3):333–339.
Gehrig, PA, Cantrell, , Shafer, A. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman?Gynecol Oncol. 2008;111(1):41–45.
Boggess, JF, Gehrig, PA, Cantrell, L. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol. 2008;199:360–362.
Seamon, LG, Cohn, , Richardson, DL. Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol. 2008;112:1207–1213.
Lachance, JA, Everett, EN, Greer, B. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101(3): 470–475.
Truong, PT, Kader, HA, Lacy, B. The effects of age and comorbidity on treatment and outcomes in women with endometrial cancer. Am J Clin Oncol. 2005;28(2):157–164.
Alektiar, KM, Venkatraman, E, Abu-Rustum, et al . Is endometrial carcinoma intrinsically more aggressive in elderly patients?Cancer. 2003;98(11):2368–2377.
Jolly, S, Vargas, CE, Kumar, T. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006;103(1):87–93.
Creutzberg, CL, Putten, WL, Warlam-Rodenhuis, CC. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22(7):1234–1241.
Creutzberg, CL, Putten, WL, Koper, PC. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–1411.
Keys, HM, Roberts, JA, Brunetto, VL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–751.
Citron, JR, Sutton, H, Yamada, SD. Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys. 2004;59(5):1432–1438.
Alektiar, KM, Venkatraman, E, Chi, DS. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;62(1):111–117.
Fleming, GF.Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol. 2007;25(20):2983–2990.
Alvarez Secord, A, Havrilesky, LJ, Bae-Jump, V. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007;107(2):285–291.
Goldberg, H, Miller, RC, Abdah-Bortnyak, R. Rare Cancer Network. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol. 2008;108(2):298–305.
Randall, ME, Filiaci, VL, Muss, H. Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24(1):36–44.
Arterburn, , Crane, PK, Sullivan, SD. The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc. 2004;52(11):1907–1912.
Gruenigen, VE, Frasure, HE, Grandon, M. Impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol. 2005;193:1369–1375.
Everett, E, Tamini, H, Geer, B. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2003;90: 150–157.
Cassileth, BR, Lusk, EJ, Strouse, TB. Psychosocial status in chronic illness: a comparative analysis of six diagnostic groups. N Engl J Med. 1984;311(8):506–511.
Gruenigen, VE, Courneya, K, Gibbons, H. Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: a randomized trial. Gynecol Oncol. 2008;109(1):19–26.
Larsson, U, Karlsson, J, Sullivan, M. Impact of overweight and obesity on health-related quality of life: a Swedish population study. Int J Obes Relat Metab Disord. 2002;26(3):417–424.
Lopez-Garcia, E, Banegas, JR, Gutierrez-Fisac, JL. Relation between body weight and health-related quality of life among the elderly in Spain. Int J Obes. 2003;27:701–709.
Apovian, CM, Frey, CM, Wood, GC. Body mass index and physical function in older women. Obes Res. 2002;10:740–747.
Doll, HA, Petersen, SE, Stewart-Brown, SL. Obesity and physical and emotional well-being: associations between body mass index, chronic illness and the physical and mental components of the SF-36 questionnaire. Obes Res. 2000;8(2):160–170.
Fontaine, KR, Barofsk, I, Andersen, RE. Impact of weight loss on health-related quality of life. Qual Life Res. 1999;8:275–277.
Hulens, M, Vansant, G, Claessens, AL. Health-related quality of life in physically active and sedentary obese women. Am J Hum Biol. 2002;14:777–785.
Hassan, MK, Joshi, AV, Madhavan, SS. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes. 2003;27:1227–1232.
Lutgendorf, SK, Anderson, B, Rothrock, N. Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer. 2002;87:178–184.
Miller, BE, Pittman, B, Case, D. Quality of life after treatment for gynecologic malignancies: a pilot study in an outpatient clinic. Gynecol Oncol. 2002;87(2):178–184.
Chan, YM, Ngan, HY, Li, BY. A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol Oncol. 2001;83(1):10–19.
Klee, M, Machin, D. Health-related quality of life of patients with endometrial cancer who are disease-free following external irradiation. Acta Oncol. 2001;40(7):816–824.
Li, C, Samsioe, G, Iosif, C. Quality of life in endometrial cancer survivors. Maturitas. 1999;31(3):227–236.
Poll-Franse, LV, Mols, F, Essink-Bot, ML. Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys. 2007;69(1):125–132.
Blanchard, CM, Courneya, KS, Stein, K. Cancer survivors'; adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol. 2008;26(13):2198–2204.
Moore, DH, Kauderer, JT, Bell, J. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;94:368–374.